Liberté launch
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific introduces its second-generation paclitaxel-eluting coronary stent, Taxus Liberté, in 18 countries in Asia, Africa and South America, the company announces Jan. 17. The firm expects to earn a European CE mark in 2005. U.S. approval, based on the ATLAS clinical trial, is projected for early 2006. A Japan release is planned for later that year (1"The Gray Sheet" Oct. 25, 2004, p. 4). Separately, Boston Scientific announces Jan. 19 the one-millionth Taxus implantation; European and U.S. approvals were received in January 2003 and March 2004, respectively...